Soros Fund Management LLC Has $9.65 Million Position in Sanofi (NASDAQ:SNY)

Soros Fund Management LLC decreased its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 50.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 200,000 shares of the company's stock after selling 200,000 shares during the quarter. Soros Fund Management LLC's holdings in Sanofi were worth $9,646,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Synergy Asset Management LLC bought a new stake in shares of Sanofi during the fourth quarter valued at about $25,000. McClarren Financial Advisors Inc. raised its position in shares of Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock worth $28,000 after buying an additional 543 shares in the last quarter. Lee Danner & Bass Inc. acquired a new stake in shares of Sanofi in the 4th quarter worth approximately $31,000. Bessemer Group Inc. boosted its holdings in shares of Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after acquiring an additional 242 shares in the last quarter. Finally, Sierra Ocean LLC acquired a new position in shares of Sanofi during the fourth quarter valued at approximately $44,000. Institutional investors own 14.04% of the company's stock.

Analyst Ratings Changes

SNY has been the subject of a number of research reports. BNP Paribas began coverage on Sanofi in a research note on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price target for the company. Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. The Goldman Sachs Group initiated coverage on shares of Sanofi in a report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price target for the company. Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a research note on Monday. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $63.33.

Sanofi Trading Down 1.5 %

SNY traded down $0.85 during trading on Thursday, reaching $54.10. The company had a trading volume of 1,512,212 shares, compared to its average volume of 2,353,877. The firm's 50-day simple moving average is $54.52 and its 200 day simple moving average is $52.06. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The company has a market cap of $136.67 billion, a price-to-earnings ratio of 21.73, a PEG ratio of 1.01 and a beta of 0.57. Sanofi has a 12-month low of $45.80 and a 12-month high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last released its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.04. The business had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The firm's quarterly revenue was down 11.0% compared to the same quarter last year. During the same period last year, the firm posted $1.78 earnings per share. Equities research analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Thursday, June 12th. Stockholders of record on Friday, May 9th will be issued a $2.0369 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a dividend yield of 3.1%. This is a positive change from Sanofi's previous annual dividend of $1.48. Sanofi's dividend payout ratio is presently 57.14%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.